Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jan;46(1):61-69.
doi: 10.1097/DSS.0000000000002013.

Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines

Gary D Monheit  1 , Leslie Baumann  2 , Corey Maas  3 , Rhonda Rand  4 , Rebecca Down  5
Affiliations
Randomized Controlled Trial

Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines

Gary D Monheit et al. Dermatol Surg. 2020 Jan.

Abstract

Background: The aesthetic use of botulinum toxins is widely accepted in routine treatment of glabellar lines.

Objective: To strengthen existing efficacy and safety data, and examine subject satisfaction concerning abobotulinumtoxinA (ABO) treatment for moderate to severe glabellar lines.

Materials and methods: A 150-day prospective, single-dose, multicenter, randomized, parallel-group, placebo-controlled, double-blind study of 300 subjects treated with ABO (50 Units [U]). Response was defined as having no or mild glabellar lines after treatment (primary objective was Day 30 response). Glabellar line severity, onset and duration of effect, satisfaction, treatment emergent adverse events (TEAEs), and treatment-related adverse events (TRAEs) were assessed.

Results: Median time to onset of effect was 2 days. Day 30, ABO treatment response was 89% and 85% for investigator and subject assessments, respectively (p < .001 vs placebo). At Day 120, 60% of subjects demonstrated ≥1 grade improvement and 45% at Day 150. Subject satisfaction concerning glabellar line appearance was high (93%) at Day 14 and maintained by 35% through Day 150 with ABO treatment. No serious AEs were related to study treatment.

Conclusion: Most ABO-treated subjects sustained ≥1 grade glabellar line improvements over 120 days, and satisfaction was maintained by >30% of subjects throughout 150 days. ABO was well tolerated.

PubMed Disclaimer

References

    1. Dysport FDA Label. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125274s107lbl.pdf. Accessed July 2, 2019.
    1. Azzalure SmPC. 2016. Available from: https://www.medicines.org.uk/emc/medicine/21985. Accessed July 2, 2019.
    1. Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, et al. Global aesthetics consensus: botulinum toxin type A—Evidence-Based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg 2016;137:518e–529e.
    1. Rzany B, Ascher B, Monheit G. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. J Eur Acad Dermatol Venereol 2010;24(Suppl 1):1–14.
    1. Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of response of AbobotulinumtoxinA in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg 2011;37:1434–42.

Publication types

LinkOut - more resources